The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study

Lei Chen, Yanqiao Ren, Tao Sun, Yanyan Cao, Liangliang Yan, Weihua Zhang, Tao Ouyang, Chuansheng Zheng, Lei Chen, Yanqiao Ren, Tao Sun, Yanyan Cao, Liangliang Yan, Weihua Zhang, Tao Ouyang, Chuansheng Zheng

Abstract

Background: Radiofrequency ablation (RFA) is an effective treatment for single hepatocellular carcinoma (HCC), but it is difficult to use against tumors in some locations and often leads to incomplete ablation as a result of the heat-sink effect. This study was conducted to evaluate the efficacy of cryoablation compared with that of RFA in the treatment of single HCC.

Methods: This retrospective study was conducted based on the Surveillance, Epidemiology, and End Results (SEER) database. From 2004 to 2015, patients aged 40 to 79 diagnosed with HCC were included in the study. A propensity score matching (PSM) model was used to reduce selection biases.

Results: Before PSM, the median overall survival (mOS) and median cancer-specific survival (mCSS) in the RFA group were slightly longer than those in the cryoablation group (p > 0.05). In the subgroup analysis, the mOS and mCSS of patients with tumor sizes <3, 3-5, and >5 cm who received RFA treatment were longer than those of patients given cryoablation treatment, but there was no significant difference (p > 0.05). Similar results were presented in patients at American Joint Committee on Cancer (AJCC) stages I and II. After PSM, the mOS and mCSS were slightly better in the RFA group than the cryoablation group but without significant differences. Univariate and multivariate analysis showed that cryoablation treatment was not an unfavorable factor for OS and CSS before or after PSM (p > 0.05). In the multivariable competing risk model, non-cancer-specific death was taken as a competing factor and cryoablation was also not unfavorable for the survival of patients before and after PSM (p > 0.05).

Conclusion: Cryoablation is non-inferior to RFA therapy for single HCC patients without lymph node invasion or distant metastasis.

Keywords: RFA; SEER; cryoablation; efficacy; hepatocellular carcinoma.

Conflict of interest statement

All authors declare there is no conflict of interest.

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier curve of overall survival (A) and cancer‐specific survival (B) of patients with cryoablation and radiofrequency ablation (RFA) before PSM
FIGURE 2
FIGURE 2
Kaplan–Meier curve of overall survival (A) and cancer‐specific survival (B) of patients with cryoablation and radiofrequency ablation (RFA) after PSM

References

    1. Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all‐cause mortality, and cause‐specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459‐1544.
    1. Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3:1683‐1691.
    1. Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182‐236.
    1. Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261:947‐955.
    1. Peng ZW, Lin XJ, Zhang YJ, et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology. 2012;262:1022‐1033.
    1. Imai K, Beppu T, Chikamoto A, et al. Comparison between hepatic resection and radiofrequency ablation as first‐line treatment for solitary small‐sized hepatocellular carcinoma of 3 cm or less. Hepatol Res. 2013;43:853‐864.
    1. Nault JC, Sutter O, Nahon P, Ganne‐Carrie N, Seror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol. 2018;68:783‐797.
    1. Shah TT, Peters M, Eldred‐Evans D, et al. Early‐medium‐term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry. Eur Urol. 2019;76:98‐105.
    1. Bhindi B, Mason RJ, Haddad MM, et al. Outcomes after cryoablation versus partial nephrectomy for sporadic renal tumors in a solitary kidney: a propensity score analysis. Eur Urol. 2018;73:254‐259.
    1. van Munster SN, Overwater A, Haidry R, Bisschops R, Bergman J, Weusten B. Focal cryoballoon versus radiofrequency ablation of dysplastic Barrett's esophagus: impact on treatment response and postprocedural pain. Gastrointest Endosc. 2018;88:795‐803.e792.
    1. Callstrom MR, Woodrum DA, Nichols FC, et al. Multicenter study of metastatic lung tumors targeted by interventional cryoablation evaluation (SOLSTICE). J Thorac Oncol. 2020;15(7):1200‐1209.
    1. Sidana A. Cancer immunotherapy using tumor cryoablation. Immunotherapy. 2014;6:85‐93.
    1. Sabel MS. Cryo‐immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology. 2009;58:1‐11.
    1. EASL‐EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908‐943.
    1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245‐1255.
    1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020‐1022.
    1. Citterio D, Facciorusso A, Sposito C, Rota R, Bhoori S, Mazzaferro V. Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma. JAMA Surg. 2016;151:846‐853.
    1. Le Roy B, Gregoire E, Cosse C, et al. Indocyanine green retention rates at 15 min predicted hepatic decompensation in a western population. World J Surg. 2018;42:2570‐2578.
    1. Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early‐ or very early‐stage hepatocellular carcinoma: an attempted network meta‐analysis. Cochrane Database Syst Rev. 2017;3:Cd011650.
    1. Qi X, Zhao Y, Li H, Guo X, Han G. Management of hepatocellular carcinoma: an overview of major findings from meta‐analyses. Oncotarget. 2016;7:34703‐34751.
    1. Iezzi R, Pompili M, La Torre MF, et al. Radiofrequency ablation plus drug‐eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. Dig Liver Dis. 2015;47:242‐248.
    1. Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015;61:1579‐1590.
    1. Pearson AS, Izzo F, Fleming RY, et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg. 1999;178:592‐599.
    1. Xu J, Noda C, Erickson A, et al. Radiofrequency ablation vs. cryoablation for localized hepatocellular carcinoma: a propensity‐matched population study. Anticancer Res. 2018;38:6381‐6386.
    1. Ei S, Hibi T, Tanabe M, et al. Cryoablation provides superior local control of primary hepatocellular carcinomas of >2 cm compared with radiofrequency ablation and microwave coagulation therapy: an underestimated tool in the toolbox. Ann Surg Oncol. 2015;22:1294‐1300.
    1. Zeng JY, Piao XH, Zou ZY, et al. Cryoablation with drug‐loaded bead embolization in the treatment of unresectable hepatocellular carcinoma: safety and efficacy analysis. Oncotarget. 2018;9:7557‐7566.
    1. Cui W, Fan W, Huang K, et al. Large hepatocellular carcinomas: treatment with transarterial chemoembolization alone or in combination with percutaneous cryoablation. Int J Hyperthermia. 2018;35:239‐245.
    1. Ren Y, Cao Y, Ma H, et al. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single‐center retrospective case control study. BMC Cancer. 2019;19:983.
    1. Doyle A, Gorgen A, Muaddi H, et al. Outcomes of radiofrequency ablation as first‐line therapy for hepatocellular carcinoma less than 3cm in potentially transplantable patients. J Hepatol. 2019;70:866‐873.
    1. Boleslawski E, Petrovai G, Truant S, et al. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Br J Surg. 2012;99:855‐863.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit